蓝海资本 引领变革
W E   L E A D   C H A N G E S

蓝海资本聚焦于医疗健康领域具有创新性的生物医药、医疗器械和医疗科技企业的成长期和并购投资。核心团队具有丰富的科研、产业和投资的国际化经验,投资成绩屡获业界殊荣。

自2015年成立以来,蓝海资本坚持深度投资和价值创造,为被投企业带来积极改变,为投资者创造长期价值。

蓝海资本于2022年初成为联合国支持的负责任投资原则(UN PRI)的签署机构,秉承资本向善的原则,推动责任投资,持续赋能投资企业可持续发展。

Blue Ocean Capital Group (“BOCG”) is a leading investment firm focusing on innovative biotech, medical device, and med-tech companies with growth and buyout strategies. Our award-winning team has vast industry experience and international insights.

Since founded in 2015, we have adopted value-driven approach and worked closely with entrepreneurs to bring meaningful impact on their businesses and ultimately create long-term value for our investors.

BOCG has become a signatory to the United Nations-supported Principles for Responsible Investment ("UN PRI") from the beginning of 2022. As a firm believer of Capital for Good, BOCG is devoted to responsible investment and empowers sustainable development of the portfolio companies.

投资策略
Investment Strategy
投资策略
Investment Strategy
核心投资团队
A Seasoned Investment Team
核心投资团队
A Seasoned
Investment Team
获奖情况
Awards
获奖情况
Awards
投资策略 Investment Strategy
专注
FOCUS

创新型生物医药、医疗器械和医疗科技企业

Innovative biotech, medical device, med-tech companies

赋能
EMPOWER

深度投资与价值创造并行,助力企业长远发展、实现共赢

Leverage our industry know-how to support portfolio companies’ long-term growth

核心投资团队
A Seasoned Investment Team
以研究为导向
Research-oriented
丰富行业经验
Deep Industry knowledge
多个资本市场经验
Multiple capital markets experience
国际化视野
International insights
优秀的投资业绩
Proven track record
获奖情况 Awards
投中2015年度中国新锐私募股权投资机构Top10
投中2015年度中国最佳私募股权投资案例Top10(中国脐带血案例)
投中2015年度中国最佳私募股权投资新锐投资家Top10(CEO杨锋先生)
投中2016年度中国医疗及健康服务产业最佳新锐投资机构Top3
投中2016年度外资私募股权投资机构Top 30
中国并购公会2017年第十届中国并购专项奖“最佳并购融资奖”
投中2017年度“中国最佳外资私募股权投资机构Top50”
《母基金周刊》2020年“跨境投资力TOP10”奖项
CHC医疗咨询联合中信证券“2021年生物医药最佳投资机构TOP15”
CHC医疗咨询联合中信证券“2021年度最具影响力投资人TOP50”(CEO杨锋先生)
36氪“2022年最受创业者欢迎创业投资机构”
Top 10 Emerging PE Investment Institutions in China in 2015
Top 10 PE Investment Cases in China in 2015 (China Cord Blood Corporation)
Top 10 Emerging PE Investors in China in 2015 (CEO Feng Yang)
Top 3 Emerging Investment Institutions in China’s Healthcare Sector in 2016
Top 30 Foreign PE Investment Institutions in 2016
The Best M&A Financing Award at the 10th China M & A Awards in 2017 from China Mergers & Acquisitions Association
Top 50 Foreign-Funded Private Equity Investment Companies in China in 2017
FoF Weekly, TOP Investment Performance in 2020
TOP 15 Biotech Investors in 2021, by CHC & CITIC Securities
TOP50 Influential Investors in 2021 (CEO Feng Yang), by CHC & CITIC Securities
Most Founder-Friendly Investors by 36kr
蓝海观点|全球视野下的医药投资挑战与历史性机遇
2022-11-08 11:02:00
...
蓝海·Family | 瑞博生物宣布RBD7022首次人体临床试验申请在中国获批,将用于治疗高脂血症
2022-09-20 14:05:00
...
蓝海动态 | 蓝海资本正式加入联合国责任投资原则组织
2022-04-11 00:18:47
2022年4月11日,蓝海资本宣布正式签署联合国支持的“负责任投资原则”(UN Supported Principles for Responsible Investment,简称“ UN PRI”),成为中国率先加入UN PRI的专业医疗健康投资机构之一,推动责任投资、持续赋能投资企业可持续发展。...
蓝海投资|蓝海资本参投深信生物B轮融资, 推动公司mRNA药物研发和产业化
2022-03-28 13:44:46
3月28日,专注于mRNA药物及递送载体技术研发的深圳深信生物科技有限公司(以下简称“深信生物”)正式宣布完成1.2亿美元B轮融资。本轮融资由鼎晖投资、HHF华翊投资/华兴医疗产业基金领投,蓝海资本及易方达资本跟投,CPE、方圆资本等老股东持续加持。...
蓝海投资|蓝海资本参投克睿基因B轮融资
2022-01-05 09:03:33
苏州克睿基因生物科技有限公司(以下简称“克睿基因”)宣布完成6000万美元B轮融资。本轮融资由战略投资方尚珹投资(Advantech Capital)领投,蓝海资本、元禾控股、启明创投等机构跟投,华兴资本担任独家财务顾问。...
蓝海投资|蓝海资本参投洲瓴医疗Pre-A轮融资
2021-12-07 09:01:00
蓝海资本宣布参投创新型电生理技术领导者洲瓴医疗(InterHill MED®)的Pre-A轮融资。本轮融资由顺为资本领投,中科创星、蓝海资本跟投。...
蓝海投资| 蓝海资本领投科凯生命科学3.5亿元Pre-C轮融资
2021-11-03 16:26:10
...
蓝海资本 | 2021年一季度回顾
2021-06-24 17:28:32
...
蓝海•Family丨博安生物与阿斯利康中国达成重磅战略合作,助力本土抗肿瘤生物药扩面县域市场
2021-06-24 17:23:28
...
蓝海•Family丨君圣泰HTD1801获得国家药品监督管理局药品审评中心临床试验默示许可
2021-06-24 17:21:02
...
查看所有动态

我们的专业投资团队拥有丰富的行业和资本市场经验,国际化视野和优秀的投资业绩。我们致力赋能企业,与创业者一同缔造未来。

At the heart of our company is an expert-led team of investment professionals with significant industry and capital markets experience, international insights, and proven track record. We understand the importance of driving value in portfolio companies through operational expertise and improvement. Our dedicated team has deep industry knowledge to be valuable partners to our portfolio companies.

了解更多
君圣泰
HighTide Therapeutics
瑞博生物
Ribo Life Science
博安生物
Boan Biotech
科凯生命
Koka Lifesciences
希格生科
Signet Therapeutics
洲瓴医疗
InterHill Med
克睿基因
Cure Genetics
深信生物
InnoRNA
奥泰医疗
AllTech Medical Systems
金卫医疗
Golden Meditech
美中嘉和医疗
Meizhong Jiahe Hospital Mgt
成大生物(688739.SH)
Chengda Biotech (688739.SH)
微创医疗(853.HK)
Microport Scientific Corp (853.HK)
中国先锋医药(1345.HK)
China Pioneer Pharma (1345.HK)
国际脐带血库集团(CO.NYSE)
Intl Cord Blood Corporation (NYSE: CO)
泰和诚医疗集团(CCM. NYSE)
Concord Medical Services (NYSE: CCM)

深圳市福田区金田路4028号荣超经贸中心3201

3201,Rongchao Business Center, 4028 Jintian Road, Futian District, Shenzhen
Tue25 °C

上海市黄浦区湖滨路150号企业天地5号楼23楼2305

Room 2305,Level 23, 5 Corporate Avenue, 150 Hubin Road, Huangpu District, Shanghai 200021, P.R.China.
Tue15 °C

香港上环德辅道中199号无限极广场12楼

12/F, Infinitus Plaza, 199 Des Voeux Road Central, Sheung Wan, Hong Kong
Tue24 °C
加入我们 一起改变
JOIN US TO MAKE CHANGES
工作机会
加入优秀投资团队
了解更多